Health Condition 1: null- Treatment naive follicular lymphoma
Conditions
Interventions
Intervention1: Lenalidomide and Rituximab: Tab Lenalidomide 20mg d1-d21,Inj Rituximab 375 mg/m2 on d1 q 28 day .
Total 6 cycles
Control Intervention1: bendamustine and rituximab: Inj Bendamustine 90 m
Sponsors
AIIMS
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age >=18 years at diagnosis 2. low grade lymphoma-FL 3. ECOG PS â?? 0-2 4. Stage-II â?? IV ( if symptomatic) 5. Normal organ function - creatinine clearance >60ml/min; SGOT and SG PT < 2.5times of ULN
Exclusion criteria
Exclusion criteria: 1. CD 20 negative NHL 2. Grade 3b Follicular Lymphoma 3. H/o previous malignancy within the past 5 years, uncontrolled serious systemic illness, HIV infection, or active hepatitis B or C infection 4. Not willing for enrollment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoints -Complete response rate will be assessed according to IWG criteria 7. Secondary endpoints: - Overall response rate - Safety and toxicityTimepoint: Jan 2016- Jan 2018 | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints: - Overall response rateTimepoint: Jan 2016- Jan 2018;Secondary endpoints: - Safety and toxicityTimepoint: Jan 2016- Jan 2018 | — |
Countries
India
Contacts
Public ContactSusanta Kumar Paikaray
AIIMS
Outcome results
None listed